|
|
|
|
|
Levorphanol
drug data and news
Levorphanol drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Levorphanol | ||
| Brand Names/Synonyms | Antalgin; Aromarone; Cetarin; Dea No. 9220; Dea No. 9733; Dromoran; HSDB 3349; LEVORPHANOL; Lemoran; Levo-Dromoran; Levorfanol [Inn-Spanish]; Levorfanolo [Dcit]; Levorphan; Levorphanal; Levorphanol; Levorphanol Dl-Form; Levorphanol Tartrate; Levorphanolum [Inn-Latin]; Methorfinan [Czech]; Methorphinan; NU 2206; Orphan; Racemethorphanum; Racemic Dromoran; Racemorfano [Inn-Spanish]; Racemorphan; Racemorphan [Ban:Inn]; Racemorphane [Inn-French]; Racemorphanum [Inn-Latin] | ||
| Indication | For the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Levorphanol is a potent synthetic opioid analgesic indicated for the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate. Levorphanol is similar to morphine in its actions, however it is up to 8 times more potent than morphine. Levorphanol produces a degree of respiratory depression similar to that produced by morphine at equianalgesic doses, and like many mu-opioid drugs, levorphanol produces euphoria or has a positive effect on mood in many individuals. | ||
| Mechanism Of Action | Like other mu-agonist opioids it is believed to act at receptors in the periventricular and periaqueductal gray matter in both the brain and spinal cord to alter the transmission and perception of pain. | ||
| Levorphanol News (When available) |
| ||
| Dosage Forms | TABLET | ||
| Drug_Category | Narcotics; Analgesics, Opioid | ||
| Absorption | Levorphanol is well absorbed after PO administration with peak plasma concentrations occurring approximately 1 hour after dosing. | ||
| Interactions |
Interactions for Levorphanol: Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects. Respiratory depression, hypotension, and profound sedation or coma may occur. When such combined therapy is contemplated, the dose of one or both agents should be reduced. Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors. Most cases of serious or fatal adverse events involving Levo-Dromoran reported to the manufacturer or the FDA have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients, or the simultaneous administration of levorphanol with other drugs affecting respiration. The initial dose of levorphanol should be reduced by approximately 50% or more when it is given to patients along with another drug affecting respiration. Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran. In opioid-dependent patients, mixed agonist/antagonist analgesics may precipitate withdrawal symptoms. | ||
| Toxicity | Oral, rat LD50: 150 mg/kg. Signs of overdose include nausea, emesis, dizziness, respiratory depression, hypotension, urinary retention, cardiac arrhythmias, allergic reactions, skin rash, and uticaria. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Not Available | ||
| Chemical Formula | C17H23NO | ||
| Molecular Weight | 257.371 g/mol | ||
| Smiles String | CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)O | ||
| Melting Point | 198-199 °C | ||
| Water Solubility | 1840 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 3.986 | ||
| Isoelectric Point | 9.58 | ||
| Biotransformation | Levorphanol is extensively metabolized in the liver and is eliminated as the glucuronide metabolite. | ||
| Half Life | 11-16 hours | ||
| Protein Binding [%] | 40% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Levorphanol.html http://www.rxlist.com/cgi/generic2/levorphanol.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00764 | ||
| CAS Registry Number | 77-07-6 | ||
| KEGG Compound ID | C08014 | ||
| PubChem ID | SID:10214 | ||
| PharmGKB ID | PA450219 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |